In vivo Atf3 silencing ameliorated the impaired glucose metabolism and pancreatic β-cell dysfunction in ethanol-treated cells, and therefore prevented the development of T2D by reducing RNS production. Here, ATF3 is linked to type 2 diabetes mellitus.